vs

Side-by-side financial comparison of IF Bancorp, Inc. (IROQ) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

Avidity Biosciences, Inc. is the larger business by last-quarter revenue ($12.5M vs $7.3M, roughly 1.7× IF Bancorp, Inc.). IF Bancorp, Inc. runs the higher net margin — 18.1% vs -1398.3%, a 1416.4% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 16.8%). IF Bancorp, Inc. produced more free cash flow last quarter ($1.7M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 16.5%).

U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

IROQ vs RNA — Head-to-Head

Bigger by revenue
RNA
RNA
1.7× larger
RNA
$12.5M
$7.3M
IROQ
Growing faster (revenue YoY)
RNA
RNA
+417.2% gap
RNA
434.0%
16.8%
IROQ
Higher net margin
IROQ
IROQ
1416.4% more per $
IROQ
18.1%
-1398.3%
RNA
More free cash flow
IROQ
IROQ
$158.6M more FCF
IROQ
$1.7M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
16.5%
IROQ

Income Statement — Q2 FY2026 vs Q3 FY2025

Metric
IROQ
IROQ
RNA
RNA
Revenue
$7.3M
$12.5M
Net Profit
$1.3M
$-174.4M
Gross Margin
Operating Margin
24.9%
-1513.5%
Net Margin
18.1%
-1398.3%
Revenue YoY
16.8%
434.0%
Net Profit YoY
8.9%
-117.0%
EPS (diluted)
$0.41
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IROQ
IROQ
RNA
RNA
Q4 25
$7.3M
Q3 25
$7.3M
$12.5M
Q2 25
$6.9M
$3.8M
Q1 25
$6.4M
$1.6M
Q4 24
$6.3M
$3.0M
Q3 24
$6.2M
$2.3M
Q2 24
$5.7M
$2.0M
Q1 24
$5.4M
$3.5M
Net Profit
IROQ
IROQ
RNA
RNA
Q4 25
$1.3M
Q3 25
$1.4M
$-174.4M
Q2 25
$1.4M
$-157.3M
Q1 25
$1.0M
$-115.8M
Q4 24
$1.2M
$-102.3M
Q3 24
$633.0K
$-80.4M
Q2 24
$431.0K
$-70.8M
Q1 24
$708.0K
$-68.9M
Operating Margin
IROQ
IROQ
RNA
RNA
Q4 25
24.9%
Q3 25
26.0%
-1513.5%
Q2 25
29.1%
-4448.7%
Q1 25
21.7%
-8360.9%
Q4 24
26.8%
-4069.6%
Q3 24
13.7%
-4200.9%
Q2 24
9.3%
-4040.4%
Q1 24
17.6%
-2178.6%
Net Margin
IROQ
IROQ
RNA
RNA
Q4 25
18.1%
Q3 25
19.0%
-1398.3%
Q2 25
21.0%
-4089.3%
Q1 25
15.8%
-7360.0%
Q4 24
19.4%
-3439.5%
Q3 24
10.2%
-3441.7%
Q2 24
7.6%
-3461.8%
Q1 24
13.1%
-1943.4%
EPS (diluted)
IROQ
IROQ
RNA
RNA
Q4 25
$0.41
Q3 25
$0.43
$-1.27
Q2 25
$0.48
$-1.21
Q1 25
$0.31
$-0.90
Q4 24
$0.38
$-0.80
Q3 24
$0.20
$-0.65
Q2 24
$0.15
$-0.65
Q1 24
$0.22
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IROQ
IROQ
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$8.8M
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$87.4M
$1.9B
Total Assets
$830.4M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IROQ
IROQ
RNA
RNA
Q4 25
$8.8M
Q3 25
$8.0M
$350.2M
Q2 25
$20.1M
$243.9M
Q1 25
$8.9M
$254.2M
Q4 24
$5.9M
$219.9M
Q3 24
$7.8M
$370.2M
Q2 24
$9.6M
$575.8M
Q1 24
$16.1M
$471.4M
Stockholders' Equity
IROQ
IROQ
RNA
RNA
Q4 25
$87.4M
Q3 25
$84.5M
$1.9B
Q2 25
$81.8M
$1.2B
Q1 25
$78.9M
$1.3B
Q4 24
$75.9M
$1.4B
Q3 24
$78.8M
$1.5B
Q2 24
$73.9M
$1.2B
Q1 24
$72.4M
$830.9M
Total Assets
IROQ
IROQ
RNA
RNA
Q4 25
$830.4M
Q3 25
$862.3M
$2.1B
Q2 25
$887.7M
$1.4B
Q1 25
$879.1M
$1.5B
Q4 24
$885.1M
$1.6B
Q3 24
$893.4M
$1.6B
Q2 24
$887.7M
$1.3B
Q1 24
$905.0M
$951.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IROQ
IROQ
RNA
RNA
Operating Cash FlowLast quarter
$1.8M
$-156.2M
Free Cash FlowOCF − Capex
$1.7M
$-156.9M
FCF MarginFCF / Revenue
23.7%
-1257.6%
Capex IntensityCapex / Revenue
0.9%
5.7%
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters
$9.5M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IROQ
IROQ
RNA
RNA
Q4 25
$1.8M
Q3 25
$-539.0K
$-156.2M
Q2 25
$6.8M
$-199.7M
Q1 25
$1.8M
$-124.8M
Q4 24
$-155.0K
$-99.9M
Q3 24
$2.2M
$-65.6M
Q2 24
$2.3M
$-65.0M
Q1 24
$19.0K
$-70.4M
Free Cash Flow
IROQ
IROQ
RNA
RNA
Q4 25
$1.7M
Q3 25
$-582.0K
$-156.9M
Q2 25
$6.5M
$-203.0M
Q1 25
$1.8M
$-128.6M
Q4 24
$-226.0K
$-103.8M
Q3 24
$2.1M
$-67.3M
Q2 24
$2.0M
$-65.5M
Q1 24
$-67.0K
$-71.3M
FCF Margin
IROQ
IROQ
RNA
RNA
Q4 25
23.7%
Q3 25
-7.9%
-1257.6%
Q2 25
95.1%
-5277.1%
Q1 25
28.2%
-8174.3%
Q4 24
-3.6%
-3491.0%
Q3 24
33.6%
-2881.8%
Q2 24
35.7%
-3204.6%
Q1 24
-1.2%
-2012.3%
Capex Intensity
IROQ
IROQ
RNA
RNA
Q4 25
0.9%
Q3 25
0.6%
5.7%
Q2 25
3.5%
86.9%
Q1 25
0.4%
238.6%
Q4 24
1.1%
131.7%
Q3 24
1.2%
72.9%
Q2 24
4.3%
26.0%
Q1 24
1.6%
25.8%
Cash Conversion
IROQ
IROQ
RNA
RNA
Q4 25
1.36×
Q3 25
-0.39×
Q2 25
4.69×
Q1 25
1.81×
Q4 24
-0.13×
Q3 24
3.42×
Q2 24
5.30×
Q1 24
0.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons